These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 22795392)
21. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Kennedy SH; Andersen HF; Lam RW J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428 [TBL] [Abstract][Full Text] [Related]
22. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents]. Bailly D Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514 [TBL] [Abstract][Full Text] [Related]
23. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Kennedy SH; Andersen HF; Thase ME Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149 [TBL] [Abstract][Full Text] [Related]
25. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. Leuchter AF; Lesser IM; Trivedi MH; Rush AJ; Morris DW; Warden D; Fava M; Wisniewski SR; Luther JF; Perales M; Gaynes BN; Stewart JW J Psychiatr Pract; 2008 Sep; 14(5):271-80. PubMed ID: 18832958 [TBL] [Abstract][Full Text] [Related]
26. Escitalopram-associated mania in a child. Kul M; Kilincaslan A; Yumru M; Kandemir H; Adaletli H; Ceylan MF J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):119-20. PubMed ID: 18294096 [No Abstract] [Full Text] [Related]
30. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492 [TBL] [Abstract][Full Text] [Related]
31. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623 [TBL] [Abstract][Full Text] [Related]
32. The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. Bergman J; Pashinian A; Weizman A; Poyurovsky M Int Clin Psychopharmacol; 2014 Sep; 29(5):263-5. PubMed ID: 24810250 [TBL] [Abstract][Full Text] [Related]
33. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
34. [Depressive disorders in panic attack patients and their correction with escitalopram]. Levada OA; Cherednichenko NV Lik Sprava; 2005; (5-6):77-80. PubMed ID: 16396301 [TBL] [Abstract][Full Text] [Related]
35. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Pallanti S; Quercioli L; Bruscoli M J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244 [TBL] [Abstract][Full Text] [Related]
36. Hyponatremia associated with escitalopram. Covyeou JA; Jackson CW N Engl J Med; 2007 Jan; 356(1):94-5. PubMed ID: 17202465 [No Abstract] [Full Text] [Related]
37. Antidepressant drugs in cancer patients: the case of escitalopram. Tsali L; Bristianou M; Valachis A; Mauri D; Barotsis N; Bellou E J Support Oncol; 2009; 7(4):119. PubMed ID: 19731573 [No Abstract] [Full Text] [Related]